publication date: Feb. 14, 2014
A meeting of the FDA Oncologic Drugs Advisory Committee has become a rare occurrence.
Because cancer drugs are getting better, as are applications for their approval, said Richard Pazdur, director of the FDA Office of Hematology and Oncology Products.
“Drug development is much more focused, and decisions are being made on the basis of understanding the molecular basis of the disease rather than the number of responses observed in an early phase study,” Pazdur said.
|Guest Editorial |
Once Again, Hype Overshadows Data
In Breast Cancer Screening Debate
By Otis W. Brawley
Studies assessing the merits of cancer screening tend to get a lot of play in the news media. It seems every six months or so a new study makes a big splash.
|Drasga and Einhorn Respond to Single Payer Proposal Rebuttal|
In a recent article published in the Journal of Oncology Practice, oncologists Ray Drasga and Lawrence Einhorn called on their colleagues to support “an improved Medicare for all” program.
The provisions of the Affordable Care Act are insufficient to solve the crises facing American cancer patients, they wrote in the journal published by the American Society for Clinical Oncology.
Waun Ki Hong will retire as head of MD Anderson Cancer Center’s Division of Cancer Medicine
Fraser Symmans named director of CALGB Alliance Translational Research Program
American Cancer Society adds five officers to redesigned volunteer board of directors, with Pamela Meyerhoffer as chair
John Walter, president and CEO of The Leukemia & Lymphoma Society, steps down
MD Anderson’s Jim Allison awarded Szent-Györgyi Prize
AVEO Oncology and Astellas Pharma Inc. to End Tivozanib Agreement